Search > Results
You searched for: EV200050 (EV-TRACK ID)
Showing 1 - 4 of 4
Showing 1 - 4 of 4
Details | EV-TRACK ID | Experiment nr. | Species | Sample type | Separation protocol | First author | Year | EV-METRIC |
---|---|---|---|---|---|---|---|---|
EV200050 | 1/4 | Homo sapiens | Blood plasma |
qEV UF |
Vestad, Beate | 2021 | 75% | |
Study summaryFull title
All authors
Beate Vestad, Tuula A Nyman, Malene Hove-Skovsgaard, Maria Stensland, Hedda Hoel, Anne-Marie Siebke Trøseid, Trude Aspelin, Hans Christian D Aass, Maija Puhka, Johannes R Hov, Susanne Dam Nielsen, Reidun Øvstebø, Marius Trøseid
Journal
Scientific Reports
Abstract
HIV and type 2 diabetes (T2D) are both associated with gut microbiota alterations, low-grade endotox (show more...)
EV-METRIC
75% (96th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Control condition
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
Commercial method
Ultrafiltration Protein markers
EV: HSP70/ CD9
non-EV: ApoA1/ ApoB/ calnexin Proteomics
yes
Show all info
Study aim
Function/Biomarker/Identification of content (omics approaches)
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
Ultra filtration
Cut-off size (kDa)
10
Membrane type
Regenerated cellulose
Commercial kit
qEV
Characterization: Protein analysis
Protein Concentration Method
Fluorometric assay (e.g. Qubit, NanoOrange,...)
Western Blot
Detected EV-associated proteins
CD9/ HSP70
Not detected contaminants
Calnexin
ELISA
Detected contaminants
ApoA1/ ApoB
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
146
EV concentration
Yes
EM
EM-type
Transmission-EM
Image type
Close-up, Wide-field
|
||||||||
EV200050 | 2/4 | Homo sapiens | Blood plasma |
qEV UF |
Vestad, Beate | 2021 | 75% | |
Study summaryFull title
All authors
Beate Vestad, Tuula A Nyman, Malene Hove-Skovsgaard, Maria Stensland, Hedda Hoel, Anne-Marie Siebke Trøseid, Trude Aspelin, Hans Christian D Aass, Maija Puhka, Johannes R Hov, Susanne Dam Nielsen, Reidun Øvstebø, Marius Trøseid
Journal
Scientific Reports
Abstract
HIV and type 2 diabetes (T2D) are both associated with gut microbiota alterations, low-grade endotox (show more...)
EV-METRIC
75% (96th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
type 2 diabetes
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
Commercial method
Ultrafiltration Protein markers
EV: HSP70/ CD9
non-EV: ApoA1/ ApoB/ calnexin Proteomics
yes
Show all info
Study aim
Function/Biomarker/Identification of content (omics approaches)
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
Ultra filtration
Cut-off size (kDa)
10
Membrane type
Regenerated cellulose
Commercial kit
qEV
Characterization: Protein analysis
Protein Concentration Method
Fluorometric assay (e.g. Qubit, NanoOrange,...)
Western Blot
Detected EV-associated proteins
CD9/ HSP70
Not detected contaminants
calnexin
ELISA
Detected contaminants
ApoA1/ ApoB
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
141
EV concentration
Yes
EM
EM-type
Transmission-EM
Image type
Close-up, Wide-field
|
||||||||
EV200050 | 3/4 | Homo sapiens | Blood plasma |
qEV UF |
Vestad, Beate | 2021 | 75% | |
Study summaryFull title
All authors
Beate Vestad, Tuula A Nyman, Malene Hove-Skovsgaard, Maria Stensland, Hedda Hoel, Anne-Marie Siebke Trøseid, Trude Aspelin, Hans Christian D Aass, Maija Puhka, Johannes R Hov, Susanne Dam Nielsen, Reidun Øvstebø, Marius Trøseid
Journal
Scientific Reports
Abstract
HIV and type 2 diabetes (T2D) are both associated with gut microbiota alterations, low-grade endotox (show more...)
EV-METRIC
75% (96th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
HIV
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
Commercial method
Ultrafiltration Protein markers
EV: HSP70/ CD9
non-EV: ApoA1/ ApoB/ calnexin Proteomics
yes
Show all info
Study aim
Function/Biomarker/Identification of content (omics approaches)
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
Ultra filtration
Cut-off size (kDa)
10
Membrane type
Regenerated cellulose
Commercial kit
qEV
Characterization: Protein analysis
Protein Concentration Method
Fluorometric assay (e.g. Qubit, NanoOrange,...)
Western Blot
Detected EV-associated proteins
CD9/ HSP70
Not detected contaminants
calnexin
ELISA
Detected contaminants
ApoA1/ ApoB
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
154
EV concentration
Yes
EM
EM-type
Transmission-EM
Image type
Close-up, Wide-field
|
||||||||
EV200050 | 4/4 | Homo sapiens | Blood plasma |
qEV UF |
Vestad, Beate | 2021 | 75% | |
Study summaryFull title
All authors
Beate Vestad, Tuula A Nyman, Malene Hove-Skovsgaard, Maria Stensland, Hedda Hoel, Anne-Marie Siebke Trøseid, Trude Aspelin, Hans Christian D Aass, Maija Puhka, Johannes R Hov, Susanne Dam Nielsen, Reidun Øvstebø, Marius Trøseid
Journal
Scientific Reports
Abstract
HIV and type 2 diabetes (T2D) are both associated with gut microbiota alterations, low-grade endotox (show more...)
EV-METRIC
75% (96th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
HIV and type 2 diabetes
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
Commercial method
Ultrafiltration Protein markers
EV: HSP70/ CD9
non-EV: ApoA1/ ApoB/ calnexin Proteomics
yes
Show all info
Study aim
Function/Biomarker/Identification of content (omics approaches)
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
Ultra filtration
Cut-off size (kDa)
10
Membrane type
Regenerated cellulose
Commercial kit
qEV
Characterization: Protein analysis
Protein Concentration Method
Fluorometric assay (e.g. Qubit, NanoOrange,...)
Western Blot
Detected EV-associated proteins
CD9/ HSP70
Not detected contaminants
calnexin
ELISA
Detected contaminants
ApoA1/ ApoB
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
146
EV concentration
Yes
EM
EM-type
Transmission-EM
Image type
Close-up, Wide-field
|
||||||||
1 - 4 of 4 |
EV-TRACK ID | EV200050 | |||
---|---|---|---|---|
species | Homo sapiens | |||
sample type | Blood plasma | |||
condition | Control condition | type 2 diabetes | HIV | HIV and type 2 diabetes |
separation protocol | qEV Ultrafiltration | qEV Ultrafiltration | qEV Ultrafiltration | qEV Ultrafiltration |
Exp. nr. | 1 | 2 | 3 | 4 |
EV-METRIC % | 75 | 75 | 75 | 75 |